Chronic Heart Failure
Conditions
Keywords
heart failure, growth hormone, testosterone, insulin resistance, thyroid hormones, survival
Brief summary
The objective of this study is to determine whether the presence of metabolic alteration and anabolic deficiencies in patients with chronic heart failure are able to identify a subset of patients with poor outcome.
Detailed description
Despite the effectiveness of the neurohormonal model to explain the progression of heart failure and the many insights that it provided for the development of new therapies, there is increasing clinical evidence that suggests that our current models fail to completely explain the disease progression. Thus, neurohormonal models may be necessary but not sufficient to explain all aspects of disease progression in the failing heart. There is evidence suggesting that in heart failure there is a metabolic imbalance characterized by the predominance of the catabolic status over the anabolic drive. Aim of this registry is to determine the prevalence of hormone/metabolic deficiencies in heart failure patients and to look for possible association with clinical variables. Moreover, enrolled patients will be followed up for a mean of 2,5 years in order to collect outcome data including all-cause mortality, cardiovascular mortality, hospitalizations. This is a multi-center observational study involving several Italian Department of Cardiology, Endocrinology, Internal Medicine
Interventions
None listed
Sponsors
Federico II University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients of either sex affected by CHF, secondary to ischemic or idiopathic dilated cardiomyopathy * left ventricle ejection fraction 40% or less
Exclusion criteria
* severe liver disease * serum creatinine levels \>2.5 mg/dl * history of active cancer with life expectancy below 1 year * acute coronary syndrome in the previous 6 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| all-cause mortality and hospitalization | every six months (up to 5 years) | outcome assessed during scheduled visits or phone calls |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| cardiovascular mortality | every six months (up to 5 years) | outcome assessed during scheduled visits or phone calls |
| cardiovascular hospitalizations | every six months (up to 5 years) | outcome assessed during scheduled visits or phone calls |
Other
| Measure | Time frame | Description |
|---|---|---|
| reduction in peak oxygen consumption | every six months (up to 5 years) | outcome assessed during scheduled visits |
| left ventricular volumes | every six months (up to 5 years) | outcome assessed during scheduled visits |
Countries
Italy
Contacts
Primary ContactAntonio Cittadini, Professor
Backup ContactMichele Arcopinto, MD
Outcome results
None listed